DMKC Advisory Services LLC Acquires 13,721 Shares of Abbott Laboratories $ABT

Key Points

• DMKC Advisory Services LLC increased its stake in Abbott Laboratories by 88.1%, acquiring an additional 13,721 shares in the second quarter, bringing its total holdings to 29,289 shares valued at approximately $3.98 million.
• Abbott Laboratories announced a quarterly dividend of $0.59 per share, with an annualized yield of 1.8%, making this dividend payment relevant for investors on the record as of October 15th.
• Institutional investors own 75.18% of Abbott Laboratories' stock, indicating strong interest and confidence in the company's future performance.

DMKC Advisory Services LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 88.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,289 shares of the healthcare product maker's stock after acquiring an additional 13,721 shares during the quarter. Abbott Laboratories accounts for 2.1% of DMKC Advisory Services LLC's portfolio, making the stock its 16th biggest holding. DMKC Advisory Services LLC's holdings in Abbott Laboratories were worth $3,984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ABT. Kelly Financial Services LLC bought a new position in Abbott Laboratories in the 1st quarter worth about $216,000. Edge Financial Advisors LLC boosted its holdings in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after purchasing an additional 81 shares during the period. Avanza Fonder AB raised its position in Abbott Laboratories by 0.4% during the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock valued at $22,904,000 after purchasing an additional 655 shares in the last quarter. SageView Advisory Group LLC raised its position in Abbott Laboratories by 18.6% during the 1st quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock valued at $2,427,000 after purchasing an additional 2,873 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Abbott Laboratories by 12.4% during the 2nd quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock valued at $91,109,000 after purchasing an additional 73,780 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ABT has been the topic of several research reports. Raymond James Financial cut their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Wells Fargo & Company reduced their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. The Goldman Sachs Group boosted their price objective on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Royal Bank Of Canada lifted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $145.39.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Down 0.3%

Abbott Laboratories stock opened at $133.53 on Thursday. The business has a fifty day moving average price of $131.63 and a 200-day moving average price of $131.24. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock has a market capitalization of $232.39 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.